Hangzhou Tigermed Consulting (stock code: 300347.SZ) plans to repurchase A-shares with a total value of 500 million to 1 billion yuan. The repurchase price will not exceed 60 yuan per share.

date
19:26 13/05/2026
avatar
GMT Eight
Tiger Pharmaceuticals (300347.SZ) announced that the company plans to repurchase a portion of its A shares through centralized bidding transactions or other methods allowed by laws and regulations using its own funds or self-raised funds. The purpose of the repurchase is for the implementation of an A-share equity incentive plan or A-share employee shareholding plan, as well as to reduce the company's registered capital. The total amount of funds for repurchase is not less than 500 million yuan and not more than 1 billion yuan, with a repurchase price not exceeding 60.00 yuan per share (including 60.00 yuan per share).
Hangzhou Tigermed Consulting (300347.SZ) announced that the company plans to use its own funds or self-raised funds to repurchase a portion of the company's A shares through centralized bidding or other methods allowed by laws and regulations. The purpose of the repurchase is to implement A-share equity incentive plans or A-share employee stock ownership plans, as well as to reduce the company's registered capital. The total amount of funds earmarked for repurchase will be no less than 500 million yuan and no more than 1 billion yuan, with a repurchase price not exceeding 60.00 yuan per share (including 60.00 yuan per share).